PRS-343 in Combination With Atezolizumab in HER2-Positive Solid Tumors

Part of paid clinical trials in Los Angeles, California.

Sponsor
Pieris Pharmaceuticals, Inc.
Study ID
NCT03650348
Phase
PHASE1
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

Study Details

A Phase 1b, open-label, dose escalation study of PRS-343 in combination with atezolizumab in patients with HER2-positive advanced or metastatic solid tumors.

Key Dates

Start date
Aug 21, 2018
Status verified
Apr 2024
Primary completion
Aug 11, 2022
Completion
Aug 11, 2022

Study Design

Enrollment
41 participants (actual)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: PRS-343 in Combination with Atezolizumab

Primary Outcome Measure

Incidence of DLTs and recommended Phase 2 dose (RP2D) of PRS-343 administered in combination with atezolizumab [ Time Frame: Up to 36 months ]

Locations (8)

FacilityCityStateZIPSite coordinators
USC Norris Comprehensive Cancer CenterLos AngelesCalifornia90033-
Hoag Memorial Hospital PresbyterianNewport BeachCalifornia92663-
UCLA HealthSanta MonicaCalifornia90404-
Ochsner Cancer InstituteNew OrleansLouisiana70121-
Memorial Sloan Kettering Cancer CenterNew YorkNew York10065-
The Ohio State University Comprehensive Cancer CenterColumbusOhio43202-
M.D. Anderson Cancer CenterHoustonTexas77030-
NEXT OncologySan AntonioTexas78240-

Find similar trials in Los Angeles, CA

By condition
Breast cancer
By specialty
OncologyBreast oncologyWomen's health
By research site
USC Norris Comprehensive Cancer Center· Los Angeles, CAHoag Memorial Hospital Presbyterian· Newport Beach, CAUCLA Health· Santa Monica, CAOchsner Cancer Institute· New Orleans, LAMemorial Sloan Kettering Cancer Center· New York, NYThe Ohio State University Comprehensive Cancer Center· Columbus, OH

Related Studies